SYK and neoplasm: Previously, we have shown that dasatinib (targets mainly SRC family kinases at low concentrations) and PRT318 (highly specific for SYK) exert anti-tumor activity primarily by affecting cell cycle with minimal impact on cell viability [12, 13].